The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?

References

• Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J. Clin. Oncol.22, 3608–3617 (2004).
   PubMed Web of Science ®Google Scholar
• Khuntia D, Brown P, Li J, Mehta MP. Whole-brain radiotherapy in the management of brain metastasis. J. Clin. Oncol.24(8), 1295–1304 (2006).
   PubMed Web of Science ®Google Scholar
• Phillips TL, Scott CB, Leibel SA, Rotman M, Weigensberg IJ. Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: report of RTOG trial 89-05. Int. J. Radiat. Oncol. Biol. Phys.33(2), 339–348 (1995).
   PubMed Web of Science ®Google Scholar
• Bendell JC, Domchek SM, Burstein HJ et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer97, 2972–2977 (2003).
   PubMed Web of Science ®Google Scholar
• Miller KD, Weathers T, Haney LG et al. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann. Oncol.14, 1072–1077 (2003).
   PubMed Web of Science ®Google Scholar
• Lai R, Dang CT, Malkin MG, Abrey LE. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer101(4), 810–816 (2004).
   PubMed Web of Science ®Google Scholar
• Trudeau ME, Crump M, Charpentier D et al. Temozolomide in metastatic breast cancer (MBC): a Phase II trial of the National Cancer Institute of Canada – Clinical Trials Group (NCIC-CTG). Ann. Oncol.17, 952–995 (2006).
   PubMed Web of Science ®Google Scholar
• Rivera E, Meyers C, Groves M et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast cancer. Cancer107, 1348–1354 (2006).
   PubMed Web of Science ®Google Scholar
• Addeo R, Caraglia M, Faiola V et al. Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of life. BMC Cancer7, 18 (2007).
   PubMed Web of Science ®Google Scholar
• Antonadou D, Paraskevaidis M, Sarris G et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J. Clin. Oncol.20, 3644–3650 (2002).
   PubMed Web of Science ®Google Scholar
• Wedge SR, Porteous JK, Glaser MG, Marcus K, Newlands ES. In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs8, 92–97 (1997).
   PubMed Web of Science ®Google Scholar
• Addeo R, De Rosa C, Faiola V et al. Phase II trial of temozolomide using protracted low-dose and whole-brain radiotherapy for non small cell lung cancer and breast cancer patients with brain metastases. Cancer113(9), 2524–2531 (2008).
   PubMed Web of Science ®Google Scholar
• Park YH, Park MJ, Ji SH et al. Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br. J. Cancer100(6), 894–900 (2009).
   PubMed Web of Science ®Google Scholar
• Kyoda S, Kinoshita S, Takeyama H, Uchida K, Morikawa T. HER-2 protein overexpression in metastatic breast carcinoma found at autopsy. Jpn. J. Clin. Oncol.38(11), 743–747 (2008).
   PubMed Web of Science ®Google Scholar
• Cabioglu N, Sahin AA, Morandi P. Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications. Ann. Oncol.20, 1013–1019 (2009).
   PubMed Web of Science ®Google Scholar
• Ito Y, Tokudome N, Sugihara T, Takahashi S, Hatake K. Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer? Br. Cancer14(2), 156–162 (2007).
   PubMedGoogle Scholar
• Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med.355, 2733–2743 (2006).
   PubMed Web of Science ®Google Scholar
• Gril B, Palmieri D, Bronder JL et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J. Natl Cancer Inst.100, 1092–1103 (2008).
   PubMed Web of Science ®Google Scholar
• Lin NU, Carey LA, Liu MC et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol.26(12), 1993–1999 (2008).
   PubMed Web of Science ®Google Scholar
• Lin NU, Diéras V, Paul D et al. Multicenter Phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin. Cancer Res.15(4), 1452–1459 (2009).
   PubMed Web of Science ®Google Scholar
• Nathoo N, Chahlavi A, Barnett GH et al. Pathobiology of brain metastases. J. Clin. Pathol.58, 237–242 (2005).
   PubMed Web of Science ®Google Scholar
• Yang SX. Bevacizumab and breast cancer: current therapeutic progress and future perspectives. Expert Rev. Anticancer Ther.9(12), 1715–1725 (2009).
   PubMed Web of Science ®Google Scholar
• Labidi SI, Bachelot T, Ray-Coquard I et al. Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series. Clin. Breast Cancer9(2), 118–121 (2009).
   PubMed Web of Science ®Google Scholar
• Rini BI. Sunitinib. Expert Opin. Pharmacother.8(14), 2359–2369 (2007).
   PubMed Web of Science ®Google Scholar
• Abrams TJ, Murray LJ, Pesenti E et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with ‘standard of care’ therapeutic agents for the treatment of breast cancer. Mol. Cancer Ther.10, 1011–1021 (2003).
   Google Scholar
• Medioni J, Cojocarasu O, Belcaceres JL, Halimi P, Oudard S. Complete cerebral response with sunitinib for metastatic renal cell carcinoma. Ann. Oncol.18(7), 1282–1283 (2007).
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Elias AD, Rugo HS et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol.26(11), 1810–1816 (2008).
   PubMed Web of Science ®Google Scholar
• Patyna S, Peng J. Distribution of sunitinib and its active metabolite in brain and spinal cord tissue following oral or intravenous administration in rodents and monkeys. Eur. J. Cancer4, 21 (2006).
   Google Scholar